iCad (NSDQ:ICAD) said Monday it launched its iReveal breast density software designed to deliver reproducible breast density assessments. The module was designed to be used with the company’s PowerLook advanced mammography platform.
The software will help treat an estimated 40% of women in the U.S. who have dense breast tissue that can mask the presence of cancer during standard mammography, the Nashua, N.H.-based company said.
“The launch of iReveal is another example of iCad’s commitment to meeting the ever-expanding needs of healthcare providers and patients in cancer detection and treatment. This solution offers a standardized breast density measurement that eliminates reader variability and classifies density using the same factors considered by experienced radiologists. With iReveal, radiologists may be better able to identify women with dense breasts who experience decreased sensitivity to cancer detection with mammography,” CEO Ken Ferry said in a press release.
The iReveal module automates the analytical approach used by radiologists to examine dense breast tissue, based on the American College of Radiology’s breast imaging reporting and data system, iCad said.
“With the increasing support for the reporting of breast density across the U.S., there is a significant opportunity to drive adoption of iReveal by existing users of the PowerLook Amp platform and with new customers, which represents an incremental $100 million market opportunity over the next few years. Longer-term, we plan to integrate the iReveal technology into our Tomosynthesis Cad product, which is the next large growth opportunity for our cancer detection business,” Ferry said in prepared remarks.